YU58392A - Peptidi koji se koriste u regulaciji imunoloških i nervnih sistema - Google Patents
Peptidi koji se koriste u regulaciji imunoloških i nervnih sistemaInfo
- Publication number
- YU58392A YU58392A YU58392A YU58392A YU58392A YU 58392 A YU58392 A YU 58392A YU 58392 A YU58392 A YU 58392A YU 58392 A YU58392 A YU 58392A YU 58392 A YU58392 A YU 58392A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- pro
- hydroxy
- alkyl
- pentapeptides
- halogen
- Prior art date
Links
- 210000000653 nervous system Anatomy 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000001900 immune effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- JFOWDKWFHZIMTR-RUCXOUQFSA-N (2s)-2-aminopentanedioic acid;(2s)-2,5-diamino-5-oxopentanoic acid Chemical group OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(O)=O JFOWDKWFHZIMTR-RUCXOUQFSA-N 0.000 abstract 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- 150000008575 L-amino acids Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005741 alkyl alkenyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/66—Thymopoietins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/708,035 US5215964A (en) | 1991-06-03 | 1991-06-03 | Peptides useful in regulating the immune and nervous systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU58392A true YU58392A (sh) | 1995-03-27 |
Family
ID=24844123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU58392A YU58392A (sh) | 1991-06-03 | 1992-06-03 | Peptidi koji se koriste u regulaciji imunoloških i nervnih sistema |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5215964A (OSRAM) |
| EP (1) | EP0517464A1 (OSRAM) |
| JP (1) | JPH06501955A (OSRAM) |
| CN (1) | CN1068334A (OSRAM) |
| AU (1) | AU653838B2 (OSRAM) |
| BR (1) | BR9205281A (OSRAM) |
| CA (1) | CA2088664A1 (OSRAM) |
| CZ (1) | CZ7793A3 (OSRAM) |
| FI (1) | FI930342L (OSRAM) |
| HU (1) | HUT63856A (OSRAM) |
| IE (1) | IE921781A1 (OSRAM) |
| IL (1) | IL102065A0 (OSRAM) |
| MX (1) | MX9202643A (OSRAM) |
| NO (1) | NO930359L (OSRAM) |
| NZ (1) | NZ242993A (OSRAM) |
| SK (1) | SK4093A3 (OSRAM) |
| TW (1) | TW222281B (OSRAM) |
| WO (1) | WO1992021366A1 (OSRAM) |
| YU (1) | YU58392A (OSRAM) |
| ZA (1) | ZA924023B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003067A1 (en) * | 1993-07-21 | 1995-02-02 | Khavinson Vladimir Khatskelevi | Pharmaceutical with immunomodulating activity |
| GB9425582D0 (en) * | 1994-12-19 | 1995-02-15 | Iaf Biochem Int | Peptides having immunomodulatory activity |
| AU4222200A (en) * | 1999-04-15 | 2000-11-02 | Thymon L.L.C. | Nonextractive method of assaying thymopoietin |
| CN104311640B (zh) * | 2014-11-27 | 2017-08-25 | 上海弭阳生物技术有限公司 | 一种免疫修复15肽、其制备方法及其应用 |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE263994C (OSRAM) * | ||||
| DE2639941C2 (de) * | 1976-09-04 | 1984-10-04 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung von Phosphin |
| US4397842A (en) * | 1980-03-13 | 1983-08-09 | Ortho Pharmaceutical Corporation | Peptides having thymopoietin-like activity |
| US4505853A (en) * | 1983-11-18 | 1985-03-19 | Ortho Pharmaceutical Corporation | Enzyme-resistant immunomodulatory peptides |
| US4629723A (en) * | 1984-06-27 | 1986-12-16 | Ortho Pharmaceutical Corporation | Potent thymopentin analogs |
| DD263994A1 (de) * | 1987-07-09 | 1989-01-18 | Univ Halle Wittenberg | Verfahren zur herstellung von oligodesoxyribonucleotiden zur splenopentinexpression |
| DD296084A5 (de) * | 1989-07-27 | 1991-11-21 | Adw | Verfahren zur herstellung von humanen spleninderivaten |
| WO1992009628A1 (en) * | 1990-11-23 | 1992-06-11 | Immunodynamics, Inc. | Synthetic immunoactive peptides having immunomodulating and therapeutic activities |
-
1991
- 1991-06-03 US US07/708,035 patent/US5215964A/en not_active Expired - Fee Related
-
1992
- 1992-05-28 WO PCT/US1992/004484 patent/WO1992021366A1/en not_active Ceased
- 1992-05-28 BR BR9205281A patent/BR9205281A/pt not_active Application Discontinuation
- 1992-05-28 CZ CZ9377A patent/CZ7793A3/cs unknown
- 1992-05-28 HU HU9300278A patent/HUT63856A/hu unknown
- 1992-05-28 AU AU20125/92A patent/AU653838B2/en not_active Ceased
- 1992-05-28 CA CA002088664A patent/CA2088664A1/en not_active Abandoned
- 1992-05-28 FI FI930342A patent/FI930342L/fi not_active Application Discontinuation
- 1992-05-28 SK SK4093A patent/SK4093A3/sk unknown
- 1992-05-28 JP JP5500559A patent/JPH06501955A/ja active Pending
- 1992-06-01 IL IL102065A patent/IL102065A0/xx unknown
- 1992-06-01 EP EP19920305000 patent/EP0517464A1/en not_active Ceased
- 1992-06-02 ZA ZA924023A patent/ZA924023B/xx unknown
- 1992-06-02 NZ NZ242993A patent/NZ242993A/en unknown
- 1992-06-03 YU YU58392A patent/YU58392A/sh unknown
- 1992-06-03 CN CN92105676A patent/CN1068334A/zh active Pending
- 1992-06-03 MX MX9202643A patent/MX9202643A/es unknown
- 1992-07-01 IE IE178192A patent/IE921781A1/en not_active Application Discontinuation
- 1992-07-28 TW TW081105931A patent/TW222281B/zh active
-
1993
- 1993-02-02 NO NO93930359A patent/NO930359L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9205281A (pt) | 1993-07-27 |
| CA2088664A1 (en) | 1992-12-04 |
| NO930359L (no) | 1993-03-18 |
| IE921781A1 (en) | 1992-12-16 |
| ZA924023B (en) | 1993-02-24 |
| FI930342A7 (fi) | 1993-01-27 |
| AU653838B2 (en) | 1994-10-13 |
| HUT63856A (en) | 1993-10-28 |
| AU2012592A (en) | 1993-01-08 |
| NO930359D0 (no) | 1993-02-02 |
| FI930342A0 (fi) | 1993-01-27 |
| CZ7793A3 (en) | 1993-12-15 |
| US5215964A (en) | 1993-06-01 |
| EP0517464A1 (en) | 1992-12-09 |
| JPH06501955A (ja) | 1994-03-03 |
| FI930342L (fi) | 1993-01-27 |
| SK4093A3 (en) | 1993-09-08 |
| TW222281B (OSRAM) | 1994-04-11 |
| IL102065A0 (en) | 1993-01-14 |
| NZ242993A (en) | 1995-09-26 |
| CN1068334A (zh) | 1993-01-27 |
| MX9202643A (es) | 1994-08-31 |
| HU9300278D0 (en) | 1993-04-28 |
| WO1992021366A1 (en) | 1992-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH18967A (en) | Peptides and pharmaceutical composition thereof | |
| DE69417252D1 (de) | Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17 | |
| CO4790174A1 (es) | Analogos del peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen | |
| GR3035067T3 (en) | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins. | |
| IL75637A0 (en) | Thymopentin analogs and pharmaceutical compositions containing them | |
| IL154995A0 (en) | Polypeptide bombesin antagonists, their preparation and pharmaceutical preparations containing them | |
| IL91691A (en) | T cell growth factor, method for the preparation thereof and pharmaceutical compositions containing the same | |
| YU58392A (sh) | Peptidi koji se koriste u regulaciji imunoloških i nervnih sistema | |
| GB1297398A (OSRAM) | ||
| MY104909A (en) | Peptide compounds. | |
| IL65371A (en) | Peptides which inhibit the release of gonadotropins,their preparation and pharmaceutical compositions containing them | |
| GB1536677A (en) | Peptide derivatives having a antihypertensive effect and process for their manufacture | |
| GB1489326A (en) | Pharmaceutically active polypeptides | |
| NO960710L (no) | Nye tripeptider nyttige i immun- og CNS-terapi | |
| GB1158724A (en) | Amino Acid Derivatives | |
| CO4930283A1 (es) | Analogos peptidos lh-rh, su empleo y composiciones farmaceu- ticas que los contienen | |
| KR950701647A (ko) | 필리스타타 히베르날리스(Filistata hibernalis)로부터의 칼슘 채널 차단 폴리펩티드(CALCIUM CHANNEL BLOCKING POLYPEPTIDES FROM FILISTATA HIBERNALIS) | |
| Csaba et al. | Suitability of oligopeptides for induction of hormonal imprinting—implications on receptor and hormone evolution | |
| GB1363801A (en) | Peptides and their preparation | |
| Li et al. | Role for protein kinase C activation in IgA B cell terminal differentiation | |
| GB895345A (en) | Polypeptides | |
| NO156012C (no) | Analogifremgangsmaate til fremstilling av nye terapeutisk virksomme pyrimido(1,6-a)indol-5-eddiksyrederivater. | |
| IE35077B1 (en) | Polypeptides and their derivatives | |
| ATE24185T1 (de) | Metorphamid, ein dem morphin aehnliches peptid. | |
| AR009422A1 (es) | Analogos peptidos lh-rh, su empleo y composiciones farmaceuticas en las cuales estan presentes |